Page Title
Drug Development Pipeline
Adrulipase (formerly MS1819-SD)
Status
DiscontinuedTherapeutic Approach
Nutritional-GI
Adrulipase (formerly MS1819-SD) is a non-porcine, meaning not pig-derived, enzyme for individuals with CF who have exocrine pancreatic insufficiency. It is a man-made version of a lipase enzyme taken from the yeast Yarrowia lipolytica. This drug does not contain any animal products.
Status
A Phase 2 study in people with CF compared adrulipase to currently available porcine-derived enzymes. No further development in CF is planned at this time.
Sponsor
This program was sponsored by Entero Therapeutics (formerly First Wave Biopharma). It was conducted within the Therapeutics Development Network (TDN).

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More